Efficacy and safety of iGlarLixi versus IDegAsp : Results of a systematic literature review and indirect treatment comparison-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of iGlarLixi versus IDegAsp : Results of a systematic literature review and indirect treatment comparison

Published:2021-08-31 Issue:12 Volume:23 Page:2660-2669
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Home Philip D.¹^ORCID,Mehta Roopa²^ORCID,Hafidh Khadija A. S.³,Gurova Olesya Y.⁴,Alvarez Agustina⁵,Serafini Paul⁶,Pourrahmat Mir‐Masoud⁶

Affiliation:

1. Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK

2. Metabolic Diseases Research Unit (UIEM) National Institute of Medical Sciences and Nutrition Salvador Zubiran (INCMNSZ) Mexico City Mexico

3. Department of Internal Medicine, Diabetology Unit Rashid Hospital, Dubai Health Authority Dubai United Arab Emirates

4. Sechenov First Moscow State Medical University Moscow Russia

5. Sanofi Buenos Aires Argentina

6. Evidinno Outcomes Research Inc. Vancouver British Columbia Canada

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14518

Reference31 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

2. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

4. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

5. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial;Diabetes, Obesity and Metabolism;2024-06-22

2. Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus;Diabetes Therapy;2023-10-06

3. Issues of insulin therapy for type 2 diabetes and ways to solve them;INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine);2023-06-01

4. Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries;Diabetes, Obesity and Metabolism;2023-05-30

5. Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials;Review of Diabetic Studies;2023-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3